Hemorrhoids are common, uncomfortable and not exactly anyone’s favorite dinner-table topic. But new guidance from the American Gastroenterological Association offers a practical reminder: preventing and managing them often starts with fiber, bowel habits and proper diagnosis, not just the products people reach for after symptoms begin.
The new clinical practice update, published in Clinical Gastroenterology and Hepatology, is an expert review, not a clinical trial. It does not show that fiber prevents every case of hemorrhoids or that over-the-counter products never help. Instead, it summarizes current evidence and expert guidance on how hemorrhoids should be diagnosed and treated.
The AGA says lifestyle changes should come first for most people. That includes increasing dietary fiber, reducing time spent sitting on the toilet and avoiding straining during bowel movements. Those steps can help make stool easier to pass and may reduce pressure that contributes to hemorrhoid symptoms.
The guidance also notes that some common remedies have weaker evidence than many people may assume. Sitz baths and over-the-counter topical products may provide symptom relief for some people, but the update says data supporting their effectiveness are limited. Topical steroids should also be used cautiously and not for more than two weeks because of the risk of skin thinning and irritation.
Another key point is diagnosis. The AGA recommends a physical exam, often including anoscopy, to confirm hemorrhoids before treatment. That matters because rectal bleeding, pain or changes in bowel habits can have causes other than hemorrhoids.
For more persistent or severe cases, the update says office-based procedures, such as banding, or surgery may be needed. Hemorrhoids are also common during pregnancy and are usually managed conservatively with diet and symptom relief.
This was an American Gastroenterological Association expert guidance document, not a new clinical trial. Most authors reported no conflicts, though one author disclosed consulting or financial relationships with several pharmaceutical and medical device companies.